We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$449M
AUM Growth
-$122M
Cap. Flow
-$33.8M
Cap. Flow %
-7.52%
Top 10 Hldgs %
73.91%
Holding
54
New
15
Increased
8
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
SNWV
SANUWAVE Health Inc
SNWV
+$31.9M
2
IMNM icon
Immunome
IMNM
+$14.5M
3
LQDA icon
Liquidia Corp
LQDA
+$8.2M
4
ANIK icon
Anika Therapeutics
ANIK
+$6.57M
5
LRMR icon
Larimar Therapeutics
LRMR
+$6.05M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$58M
2
OCUL icon
Ocular Therapeutix
OCUL
+$21.1M
3
JSPR icon
Jasper Therapeutics
JSPR
+$8.55M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$8.35M
5
TRVI icon
Trevi Therapeutics
TRVI
+$7.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.58%
2 Miscellaneous 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$105M 23.42%
3,955,000
-35,000
-0.9% -$1.05M
ETON icon
2
Eton Pharmaceutcials
ETON
$1.79B
$37M 8.24%
2,852,070
– –
SNWV
3
SANUWAVE Health Inc
SNWV
$40.1M
$34.4M 7.65%
+972,002
New +$31.9M
LQDA icon
4
Liquidia Corp
LQDA
$6.26B
$33.3M 7.42%
2,260,000
+561,858
+33% +$8.2M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.75B
$26M 5.78%
490,000
-10,000
-2% -$555K
CDXS icon
6
Codexis
CDXS
$182M
$25.6M 5.69%
9,500,000
+660,000
+7% +$2.56M
IMNM icon
7
Immunome
IMNM
$3.28B
$23.9M 5.32%
3,550,000
+1,510,000
+74% +$14.5M
TGTX icon
8
TG Therapeutics
TGTX
$8.53B
$21.1M 4.7%
535,000
-1,725,000
-76% -$58M
ARVN icon
9
Arvinas
ARVN
$604M
$13.9M 3.09%
1,975,000
+350,000
+22% +$5.48M
OCUL icon
10
Ocular Therapeutix
OCUL
$2.38B
$11.7M 2.6%
1,595,000
-2,747,500
-63% -$21.1M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.8B
$8.69M 1.93%
395,000
-85,000
-18% -$2.23M
TARA icon
12
Protara Therapeutics
TARA
$236M
$7.37M 1.64%
1,730,000
-95,000
-5% -$424K
DNA icon
13
Ginkgo Bioworks
DNA
$489M
$6.81M 1.52%
1,195,000
-5,000
-0.4% -$50.9K
ANIK icon
14
Anika Therapeutics
ANIK
$279M
$5.94M 1.32%
+395,000
New +$6.57M
PTGX icon
15
Protagonist Therapeutics
PTGX
$9.67B
$5.08M 1.13%
105,000
– –
XOMA
16
DELISTED
Xoma
XOMA
$5.04M 1.12%
253,043
+3,043
+1% +$73.3K
TRVI icon
17
Trevi Therapeutics
TRVI
$2.56B
$5M 1.11%
795,000
-1,522,500
-66% -$7.26M
PVLA
18
Palvella Therapeutics
PVLA
$2.17B
$4.82M 1.07%
+172,357
New +$3.32M
GOSS icon
19
Gossamer Bio
GOSS
$83.2M
$4.72M 1.05%
4,287,415
-202,585
-5% -$234K
ANAB icon
20
AnaptysBio
ANAB
$1.7B
$4.66M 1.04%
+250,933
New +$4.19M
IRON icon
21
Disc Medicine
IRON
$3.17B
$4.22M 0.94%
+85,000
New +$4.73M
LRMR icon
22
Larimar Therapeutics
LRMR
$421M
$4.12M 0.92%
+1,914,077
New +$6.05M
CGON icon
23
CG Oncology
CGON
$7B
$4.02M 0.89%
+163,988
New +$4.61M
SLRN
24
DELISTED
ACELYRIN
SLRN
$3.99M 0.89%
1,615,000
-620,000
-28% -$1.47M
RCEL icon
25
Avita Medical
RCEL
$319M
$3.58M 0.8%
+440,000
New +$4.11M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2025 Portfolio in Review

As of Q1 2025, Opaleye Management held 54 positions worth $449M, down 21% from $571M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Opaleye Management withdrew a net $33.8M in Q1 2025, closing 9 positions and reducing 14 holdings. Its most notable exit was Jasper Therapeutics, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in SANUWAVE Health Inc worth $34.4M.

  • Opaleye Management's largest Q1 2025 buy was SANUWAVE Health Inc: 972,002 shares worth $34.4M.
  • Opaleye Management added most to Immunome in Q1 2025, an estimated $14.5M increase.
  • Opaleye Management's biggest Q1 2025 reduction was TG Therapeutics, cutting an estimated $58M.
  • Opaleye Management fully exited Jasper Therapeutics in Q1 2025, selling an estimated $8.55M.
  • Opaleye Management's ten largest holdings make up 74% of its $449M portfolio in Q1 2025.
  • Opaleye Management opened 15 new positions and closed 9 in Q1 2025.
  • Opaleye Management's portfolio value fell 21% quarter-over-quarter to $449M.

Based on Opaleye Management's 13F filing for Q1 2025, filed 15 May 2025.